论文部分内容阅读
目前临床上用于治疗病毒性眼疾的新药很少,为了解除病人的疾苦,近年来中国科学院上海药物研究所、上海市眼病中心防治所合作研制成功了新药羟苄唑滴眼液,1986年正式投放市场。经过2年的临床应用,证明羟苄唑滴眼液是国内几个有效的抗病毒新药之一,是治疗流行性出血性结膜炎的有效药物,见效快,刺激作用极小,并对其它病毒性结膜炎、角膜炎和细菌性结膜炎有较好的疗效。羟苄唑滴眼液含盐酸羟苄唑(C_(14)H_(12)N_2OHCl)0.1%,主药化合物名称为(±)-2-(α-羟基苄基)—苯骈咪唑盐酸盐。作用机理盐酸羟苄唑的作用机理为在感染细胞内部抑制
At present, there are few new drugs clinically used to treat viral eye diseases. In order to relieve the suffering of patients, in recent years, the cooperation between Shanghai Institute of Materia Medica, Shanghai Institute of Ophthalmology and Shanghai Eye Center has succeeded in developing a new drug, Target market. After 2 years of clinical application, it has been proved that hydroxybenzazole eye drops are one of several effective new antiviral drugs in China and an effective drug for the treatment of epidemic hemorrhagic conjunctivitis. It has the advantages of quick response, minimal stimulation, Conjunctivitis, keratitis and bacterial conjunctivitis have a good effect. Benzamidazole eye drops containing hydroxybenzyl chloride (C_ (14) H_ (12) N_2OHCl) 0.1%, the name of the main drug compound as (±) -2- (α-hydroxybenzyl) . Mechanism of action The mechanism of action of hydroxybenzazole hydrochloride is in the infected cells